Literature DB >> 15173021

Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.

Michael von Bergwelt-Baildon, Joachim L Schultze, Britta Maecker, Isaura Menezes, Lee M Nadler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15173021     DOI： 10.1158/0008-5472.CAN-03-3606

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  12 in total

1.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

2.  CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.

Authors:  Michael von Bergwelt-Baildon; Alexander Shimabukuro-Vornhagen; Alexey Popov; Nela Klein-Gonzalez; Francesca Fiore; Svenja Debey; Andreas Draube; Britta Maecker; Isaura Menezes; Lee M Nadler; Joachim L Schultze
Journal:  Blood       Date:  2005-12-15       Impact factor: 22.113

3.  Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells.

Authors:  Karen S Anderson; Wanyong Zeng; Tetsuro Sasada; Jaewon Choi; Angelika B Riemer; Mei Su; Donna Drakoulakos; Yoon-Joong Kang; Vladimir Brusic; Catherine Wu; Ellis L Reinherz
Journal:  Cancer Immunol Immunother       Date:  2011-03-13       Impact factor: 6.968

4.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Authors:  Marianela Candolfi; James F Curtin; Kader Yagiz; Hikmat Assi; Mia K Wibowo; Gabrielle E Alzadeh; David Foulad; A K M G Muhammad; Sofia Salehi; Naomi Keech; Mariana Puntel; Chunyan Liu; Nicholas R Sanderson; Kurt M Kroeger; Robert Dunn; Gislaine Martins; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

5.  MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.

Authors:  Valentina Robila; Marina Ostankovitch; Michelle L Altrich-Vanlith; Alexander C Theos; Sheila Drover; Michael S Marks; Nicholas Restifo; Victor H Engelhard
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

6.  In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins.

Authors:  Hiroshi Fujiwara; J Joseph Melenhorst; Frank El Ouriaghli; Sachiko Kajigaya; Matthias Grube; Giuseppe Sconocchia; Katayoun Rezvani; David A Price; Nancy F Hensel; Daniel C Douek; A John Barrett
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

7.  Potential impact of B cells on T cell function in multiple sclerosis.

Authors:  Sara Ireland; Nancy Monson
Journal:  Mult Scler Int       Date:  2011-03-24

8.  Conditional immortalization of human B cells by CD40 ligation.

Authors:  Martina Wiesner; Caroline Zentz; Christine Mayr; Rainer Wimmer; Wolfgang Hammerschmidt; Reinhard Zeidler; Andreas Moosmann
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

9.  Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.

Authors:  Melanie L Grant; Nicholas Shields; Silke Neumann; Katrin Kramer; Andrea Bonato; Christopher Jackson; Margaret A Baird; Sarah L Young
Journal:  Clin Transl Immunology       Date:  2017-07-07

10.  Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.

Authors:  X Fan; A M Hashem; Z Chen; C Li; T Doyle; Y Zhang; Y Yi; A Farnsworth; K Xu; Z Li; R He; X Li; J Wang
Journal:  Mucosal Immunol       Date:  2014-07-23       Impact factor: 7.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.